Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
- PMID: 8634992
- DOI: 10.1002/1097-0142(19951115)76:10+<2004::aid-cncr2820761317>3.0.co;2-g
Toward an optimal algorithm for ovarian cancer screening with longitudinal tumor markers
Abstract
Stored samples from women in the Stockholm screening study were reassayed for CA125II (Centocor, Malvern, PA) and OVX1. The postmenopausal women older than age 50 without ovarian cancer were randomly split into a training set to develop a screening test based on longitudinal marker levels and a second set to validate the test. The CA125II data from each woman is summarized by the slope and intercept from a linear regression of log(CA125II) on time since first sample. The slope versus the intercept for the training set and the ovarian cancer cases formed a bivariate scatter plot. A curve was drawn on the scatter plot that separated most of the women with ovarian cancer from all other women; it delineated a screening test. The specificity of this test was examined on the validation set with a specificity of 99.8%. Bayes' theorem was used to calculate the risk of ovarian cancer (ROC) based on the intercept, slope, and assay variability. It is important to account for assay variability because it can produce large slopes over short periods of time. The maximum risk, which identified 83% (5 of 6) of the ovarian cancers detected within a year of last assay, was applied as a test to the training set and confirmed a high specificity of 99.7%. With this specificity and sensitivity, the ROC algorithm using the CA125II assay has an estimated positive predictive value of 16%, substantially greater than the positive predictive value based on a single assay. Further study is planned to confirm the sensitivity of this approach.
Similar articles
-
Ovarian cancer screening. The use of serial complementary tumor markers to improve sensitivity and specificity for early detection.Cancer. 1995 Nov 15;76(10 Suppl):2092-6. doi: 10.1002/1097-0142(19951115)76:10+<2092::aid-cncr2820761331>3.0.co;2-t. Cancer. 1995. PMID: 8635006 Review.
-
[The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].Zhonghua Fu Chan Ke Za Zhi. 2008 Dec;43(12):931-6. Zhonghua Fu Chan Ke Za Zhi. 2008. PMID: 19134334 Chinese.
-
Factors influencing serum CA125II levels in healthy postmenopausal women.Cancer Epidemiol Biomarkers Prev. 2001 May;10(5):489-93. Cancer Epidemiol Biomarkers Prev. 2001. PMID: 11352859
-
Status of tumor markers in ovarian cancer screening.J Clin Oncol. 2003 May 15;21(10 Suppl):200s-205s. doi: 10.1200/JCO.2003.01.068. J Clin Oncol. 2003. PMID: 12743135 Review.
-
Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements.Ann Univ Mariae Curie Sklodowska Med. 2002;57(1):113-31. Ann Univ Mariae Curie Sklodowska Med. 2002. PMID: 12898913
Cited by
-
Use of Biomarkers in Screening for Cancer.EJIFCC. 2010 Mar 25;21(1):1-12. eCollection 2010 Mar. EJIFCC. 2010. PMID: 27683350 Free PMC article.
-
Label-Free Detection and Spectrometrically Quantitative Analysis of the Cancer Biomarker CA125 Based on Lyotropic Chromonic Liquid Crystal.Biosensors (Basel). 2021 Aug 11;11(8):271. doi: 10.3390/bios11080271. Biosensors (Basel). 2021. PMID: 34436073 Free PMC article.
-
Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.Gynecol Oncol. 2007 Dec;107(3):526-31. doi: 10.1016/j.ygyno.2007.08.009. Epub 2007 Oct 24. Gynecol Oncol. 2007. PMID: 17920110 Free PMC article.
-
Longitudinal evaluation of CA-125 velocity and prediction of ovarian cancer.Gynecol Oncol. 2012 Apr;125(1):70-4. doi: 10.1016/j.ygyno.2011.12.440. Epub 2011 Dec 22. Gynecol Oncol. 2012. PMID: 22198243 Free PMC article. Clinical Trial.
-
Clinical Efficacy of Ovarian Cancer Screening.J Cancer. 2016 Jun 25;7(10):1311-6. doi: 10.7150/jca.14615. eCollection 2016. J Cancer. 2016. PMID: 27390606 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical